Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 27, 1997

View Archived Issues

MMP inhibitors synthesized by Otsuka

Japanese researchers describe anticoagulants

Taisho discloses promoters of NGF production

Selectin inhibitors from TBC

Selective nAChR ligands prepared by Novo Nordisk

Cytotoxic colchicine derivatives from Indena

Pfizer's new antifungal agents

Harvard College discloses vascular injury-associated gene

ArQule reports financial results for fourth quarter and year ended December 31, 1996

Cephalon announces 1996 financial results

Enzon reports second-quarter results

The Liposome Company reports fourth-quarter and 1996 results

Vion Pharmaceuticals reports fourth-quarter and year-end financial results

Mediator release inhibitors described by French investigators

Candidate proton pump inhibitor described by Dainippon

GSH deficiency linked to impaired survival in HIV/AIDS

Positive clinical results for inhaled indomethacin

Cell Genesys expands trials of AIDS gene therapy

Glaxo Wellcome evaluates ondansetron alone and in combination for emesis

Medicis acquires topical steroids

Positive results reported for VasoCare in MI

Axcan H. pylori trial nearing completion

AEterna codevelopment agreement for AE-941

Optivax phase I results reported at AAAI/AAI/CIS meeting

PathoGenesis to seek approval for tobramycin

Italian researchers report effective combination therapy for HIV-associated NHL

IND filed for SunPharm IBD treatment

Riluzole now available in France

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 8, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 8, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...